Zim Laboratories Ltd
NSE:ZIMLAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Acumentis Group Ltd
ASX:ACU
|
AU |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
|
Zim Laboratories Ltd
NSE:ZIMLAB
|
3.7B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
854.1B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
564.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
230.5B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
228.1B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
285.7B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.8B USD |
Loading...
|
|
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
86.5B GBP |
Loading...
|
Market Distribution
| Min | -3 052.3% |
| 30th Percentile | 26.9% |
| Median | 39% |
| 70th Percentile | 53.3% |
| Max | 8 269.1% |
Other Profitability Ratios
Zim Laboratories Ltd
Glance View
Zim Laboratories Ltd. is a pharmaceutical company. The company is headquartered in Nagpur, Maharashtra. The company went IPO on 2018-06-08. The firm develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. The company is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Zim Laboratories Ltd is 55.9%, which is above its 3-year median of 53.4%.
Over the last 3 years, Zim Laboratories Ltd’s Gross Margin has increased from 50.6% to 55.9%. During this period, it reached a low of 49.5% on Mar 31, 2024 and a high of 56.5% on Sep 30, 2025.
